Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

SRC-3 treatment decreased tumor growth in a Jeko-1 ibrutinib resistant mouse model. حسب Imani Bijou (18275174)

Molecular mass of peak samples of HWHF by LC-MS analysis. حسب Prawej Ansari (12191266)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. حسب Rozita Mohd (7411322)

Log reactivation results for exposures by 222 nm or 265 nm with or without UV-A 365 nm pre-treatment. حسب Daniel Ma (12698752)

24-hr treatment with 100nM M64HCl, 10μM PF573228, the combination of 100nM M64HCl and 10μM PF573228, 10μM PD98059, or the combination of 100nM M64HCl and 10μM PD98059 in migrating... حسب Sema Oncel (10152053)

الموضوعات:

24-hr treatment with 100nM M64HCl, 10μM PF573228, the combination of 100nM M64HCl and 10μM PF573228, 10μM PD98059, or the combination of 100nM M64HCl and 10μM PD98059 in migrating... حسب Sema Oncel (10152053)

الموضوعات:

Fluorescent intensity at 520 nm (RNase A/B) and 556 nm (DNase I) versus time for nucleases in DI water lysed with Lyse-It at 30% and 50% power for varying time. حسب Tonya M. Santaus (5559077)

"…<b>(A)</b> 20 pM RNase A <b>(B)</b> 46 pM RNase B, <b>(C)</b> 10.5 nM DNase I. As microwave power and time increase, nuclease activity decreases.…"

The decrease in OD_320nm over time in spectrophotometric ATPase activity assays. حسب Kai-Yin Chau (18504230)

HPLC-MS tentative identification of phenolic metabolites from the defatted extract (DE) of <i>S. malaccense</i> (SM) and <i>S. samarangense</i> (SS) leaves. حسب Fatma A. Moharram (9276104)

الموضوعات:

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease حسب Huashen Xu (13987046)

"…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …"

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease حسب Huashen Xu (13987046)

"…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …"

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease حسب Huashen Xu (13987046)

"…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …"

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease حسب Huashen Xu (13987046)

"…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …"

Effect of melatonin (50 μM) on the TGF-β1 (10 ng/mL, 72 h)-mediated TGF-β1/Smad pathway and EMT in HBdSMCs. حسب Yang Zhang (30734)

Results isoprenaline (30nM) experiment. حسب L. Cao (3526226)